Onconetix (ONCO) Interest Expenses (2021 - 2026)
Onconetix (ONCO) posted quarterly Interest Expenses of $2244.0 for Q1 2026, down 99.0% year-over-year from $223592.0 in Q1 2025, and down 99.25% quarter-over-quarter from $300069.0 in Q3 2025.
Onconetix (ONCO) Interest Expenses (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Interest Expenses for 6 consecutive years, with $2244.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 99.0% year-over-year to $2244.0; the TTM figure through Mar 2026 stood at $525410.0 (down 49.18% YoY), while the FY2025 annual figure was $20.1 million, down 1.62% from the prior year.
- Interest Expenses retreated to $2244.0 in Q1 2026 per ONCO's latest filing, from $300069.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $1653.0 billion in Q2 2022 and bottomed at $2244.0 in Q1 2026.
- Historically, Interest Expenses has averaged $110.2 billion across 5 years, with a median of $300069.0 in 2025.
- Annual changes were most pronounced in 2023 — Interest Expenses tumbled 100.0% — and 2024, when it jumped 98.07%.
- Onconetix's Interest Expenses stood at $670161.0 in 2022, then plunged by 71.87% to $188532.0 in 2023, then surged by 98.07% to $373433.0 in 2024, then dropped by 19.65% to $300069.0 in 2025, then plunged by 99.25% to $2244.0 in 2026.
- Business Quant data shows ONCO's Interest Expenses at $2244.0 in Q1 2026, $300069.0 in Q3 2025, and $223097.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 4,389.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4,389.00 |
| Jun 30, 2026 | 4,389.00 |
| Mar 31, 2026 | 2,244.00 |
| Mar 31, 2026 | 2,244.00 |
| Sep 30, 2025 | 300,069.00 |
| Sep 30, 2025 | 300,069.00 |
| Jun 30, 2025 | 223,097.00 |
| Jun 30, 2025 | 223,097.00 |
| Mar 31, 2025 | 223,592.00 |
| Mar 31, 2025 | 223,592.00 |
| Dec 31, 2024 | 373,433.00 |
| Dec 31, 2024 | 373,433.00 |
| Sep 30, 2024 | 231,656.00 |
| Sep 30, 2024 | 231,656.00 |
| Jun 30, 2024 | 205,146.00 |
| Jun 30, 2024 | 205,146.00 |
| Mar 31, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 188,532.00 |
| Dec 31, 2023 | 188,532.00 |